Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2017 09:00 ET | Source: Novartis Pharma AG

Novartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma

Study is longest follow-up to date of a BRAF and MEK inhibitor combination therapy in patients with BRAF V600-mutant metastatic melanoma[1] Study shows stable overall survival and progression-free...
June 02, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer

At a subsequent analysis of the MONALEESA-2 trial, after nearly one year of additional follow-up, Kisqali plus letrozole demonstrated median progression-free survival (PFS) of 25.3 months compared...
May 31, 2017 01:10 ET | Source: Novartis Pharma AG

Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency

Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®** Comprehensive...
May 31, 2017 01:00 ET | Source: Novartis Pharma AG

At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018

Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020 Focused and taking steps to become...
May 30, 2017 17:00 ET | Source: Novartis Pharma AG

Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients

Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months.CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the...
May 26, 2017 15:31 ET | Source: Novartis Pharma AG

Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)

In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy[1] The overall intracranial response rate in...
May 23, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids

New analyses from the FLAME study suggest dual bronchodilator Ultibro® Breezhaler® provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil (a type...
May 19, 2017 07:46 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)

Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases[1] ...
May 18, 2017 09:00 ET | Source: Novartis Pharma AG

Novartis adapte son effectif en Suisse afin de continuer à stimuler l'innovation

Dans le cadre de sa transformation actuelle en un modèle opérationnel intégré, Novartis a annoncé aujourd'hui son intention de créer quelque 350 nouveaux postes high-tech dans la production et...
May 18, 2017 09:00 ET | Source: Novartis Pharma AG

Novartis nimmt in der Schweiz Personalanpassungen vor, um die Innovationskraft weiter zu stärken

Im Rahmen der laufenden Umstellung auf ein integriertes Betriebsmodell gab Novartis heute Pläne bekannt, in den nächsten 18 Monaten in der Schweiz rund 350 neue Hightech-Positionen in der Produktion...